# Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

> **NCT00090038** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 168 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00090038
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2007-06
- **Final completion:** 2007-11
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2009-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090038, "Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00090038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*